StockData
Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc. (COGT) stock

COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.81−0.04 (-0.14%)

Close on Nov 18, 2026Market cap $4.83BP/E –Yield –

Cogent Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Cogent Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$389.09M. For fiscal 2025 it was -$333.36M. The highest annual figure on record is -$26.15M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$333.36M–
FY2024Dec 31, 2024-$275.94M–
FY2023Dec 31, 2023-$208.13M–
FY2022Dec 31, 2022-$147.84M–
FY2021Dec 31, 2021-$75.55M–
FY2020Dec 31, 2020-$82.20M–
FY2019Dec 31, 2019-$32.18M–
FY2018Dec 31, 2018-$36.01M–
FY2017Dec 31, 2017-$26.15M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$102.64M–
Q1 FY2026Mar 31, 2026-$103.61M–
Q4 FY2025Dec 31, 2025-$99.49M–
Q3 FY2025Sep 30, 2025-$83.36M–
Q2 FY2025Jun 30, 2025-$75.58M–
Q1 FY2025Mar 31, 2025-$74.93M–
Q4 FY2024Dec 31, 2024-$73.73M–
Q3 FY2024Sep 30, 2024-$75.41M–
Q2 FY2024Jun 30, 2024-$64.39M–
Q1 FY2024Mar 31, 2024-$62.40M–
Q4 FY2023Dec 31, 2023-$58.23M–
Q3 FY2023Sep 30, 2023-$59.58M–
Q2 FY2023Jun 30, 2023-$47.09M–
Q1 FY2023Mar 31, 2023-$43.24M–
Q4 FY2022Dec 31, 2022-$43.75M–
Q3 FY2022Sep 30, 2022-$36.82M–
Q2 FY2022Jun 30, 2022-$35.86M–
Q1 FY2022Mar 31, 2022-$31.42M–
Q4 FY2021Dec 31, 2021-$25.64M–
Q3 FY2021Sep 30, 2021-$19.82M–
Q2 FY2021Jun 30, 2021-$17.29M–
Q1 FY2021Mar 31, 2021-$12.80M–
Q4 FY2020Dec 31, 2020-$11.46M-611.4%
Q3 FY2020Sep 30, 2020-$57.20M–
Q2 FY2020Jun 30, 2020-$7.40M–
Q1 FY2020Mar 31, 2020-$6.14M–
Q4 FY2019Dec 31, 2019$2.24M–
Q3 FY2019Sep 30, 2019-$12.04M–
Q2 FY2019Jun 30, 2019-$10.54M–
Q1 FY2019Mar 31, 2019-$11.84M–
Q4 FY2018Dec 31, 2018-$9.00M–
Q3 FY2018Sep 30, 2018-$10.58M–
Q2 FY2018Jun 30, 2018-$9.44M–
Q1 FY2018Mar 31, 2018-$6.99M–
Q4 FY2017Dec 31, 2017-$6.88M–
Q3 FY2017Sep 30, 2017-$7.17M–
Q2 FY2017Jun 30, 2017-$6.03M–
Q1 FY2017Mar 31, 2017-$6.07M–

More Cogent Biosciences figures

See a number that looks wrong?